Amalgamated Bank Sells 344 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Amalgamated Bank lowered its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 9.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,281 shares of the company’s stock after selling 344 shares during the period. Amalgamated Bank’s holdings in USANA Health Sciences were worth $148,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Pzena Investment Management LLC grew its stake in USANA Health Sciences by 24.4% in the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock worth $44,183,000 after purchasing an additional 191,289 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of USANA Health Sciences by 32.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 109,252 shares of the company’s stock valued at $4,943,000 after buying an additional 27,053 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of USANA Health Sciences in the 2nd quarter worth about $890,000. American Century Companies Inc. increased its stake in shares of USANA Health Sciences by 12.3% in the 2nd quarter. American Century Companies Inc. now owns 159,782 shares of the company’s stock worth $7,229,000 after acquiring an additional 17,460 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its position in USANA Health Sciences by 143.1% during the 2nd quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock valued at $1,307,000 after acquiring an additional 16,999 shares during the period. 54.25% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at USANA Health Sciences

In related news, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other USANA Health Sciences news, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares in the company, valued at approximately $111,208.29. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,940 shares of company stock worth $311,670. Corporate insiders own 0.33% of the company’s stock.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $37.26 on Wednesday. The company has a market capitalization of $709.80 million, a price-to-earnings ratio of 11.61, a price-to-earnings-growth ratio of 1.27 and a beta of 0.90. USANA Health Sciences, Inc. has a one year low of $36.05 and a one year high of $59.85. The company’s 50-day moving average is $39.85 and its 200 day moving average is $43.94.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The firm had revenue of $212.87 million for the quarter, compared to analysts’ expectations of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same quarter in the previous year, the company earned $0.89 EPS. As a group, research analysts predict that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on USNA. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th. DA Davidson cut their price target on USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.